China News Network, March 3 -- Today, the eighth batch of national procurement will open bids in Lingshui County, Hainan Province. A total of 29 large varieties were involved in this national procurement, and heparin drugs were included for the first time. In addition, oseltamivir dry suspension is also among them.

Data map: Automatic drug dispensing system (picture and text unrelated) Photo by China News Agency reporter Tong Yu

The eighth batch of national procurement opened today, and heparin drugs were included for the first time

In early March, the National Organization Drug Joint Procurement Office issued the relevant documents of the National Drug Centralized Procurement Document. According to the document, the eighth batch of national procurement will begin to receive application materials at 3:3 a.m. on March 29, disclose the declaration information at 7 a.m., and confirm the supply area at 30 p.m.

The eighth batch of nationally collected varieties involved a total of 40 large varieties, covering anti-infection, heparin, antithrombotic, hypertension and other pharmaceutical fields, and heparin products were included in national procurement for the first time.

According to media reports, many of the varieties collected this time are large varieties with market sales of more than 10 billion yuan. It is worth mentioning that heparin products with a large market scale were included in the collective procurement for the first time this year, and such drugs are widely used in the treatment of a series of diseases such as myocardial infarction, cardiovascular surgery, and hemodialysis as clinical drugs for anticoagulation and antithrombosis.

Some industry experts have said that although this class of drugs has been included for the first time, the competition is very fierce. This will benefit patients taking heparin clinically and reduce medical costs.

In addition, the antiviral drug oseltamivir dry suspension is also among them.

However, this is not the first time that oseltamivir has entered centralized procurement, in the last batch of centralized procurement, oseltamivir fell from an average of 4.5 yuan per tablet to 1 yuan. The dry suspension included this time is a new dosage form launched in the market in recent years.

Data map Courtesy of Huashan Hospital affiliated to Fudan University

The average price of centralized procurement drugs has been reduced by more than 50%, and the market for proprietary Chinese medicines will also be stirred

The National Medical Security Work Conference held in January this year revealed that since the establishment of the National Medical Insurance Administration in 1, it has continued to squeeze the inflated price of drug consumables, and the average price of 2018 batches of 7 drugs has been reduced by more than 294%, and the average price of 50 batches of 3 types of consumables has been reduced by more than 4%; Combined with local alliance centralized procurement, the cumulative cost of drug consumption has exceeded 80 billion yuan.

The seventh batch of centralized procurement of drugs, with an average price reduction of 48%; The average price of spine consumables collection products was reduced by 84%; The results of insulin collection and procurement landed, benefiting more than 1000 million patients.

In addition, the proportion of patients using high-quality drugs in centralized varieties has increased from 50% to more than 90%. The space for "gold sales" of drugs continues to be compressed.

Earlier this month, the National Medical Security Administration announced a notice to deploy centralized procurement and price management of medicines in 2023. It is clear that by the end of 2023, the cumulative number of national and provincial centralized procurement drugs in each province will reach 450, of which 130 provincial-level centralized procurement drugs should be reached, and chemical drugs, proprietary Chinese medicines, and biological drugs should be covered.

It is also worth mentioning that in September 2022, the National Joint Procurement Office for Proprietary Chinese Medicines was established, and the Hubei Provincial Medical Security Bureau undertook the daily work of the Joint Procurement Office and was responsible for the specific implementation. At the same time, the "National Procurement Announcement of the Alliance of Proprietary Chinese Medicines" was released to the public, and 9 proprietary Chinese medicines in 16 categories will enter the first batch of proprietary Chinese medicines.

On the 23rd of this month, the National Joint Procurement Office of Proprietary Chinese Medicines held a communication meeting for procurement enterprises of the Alliance of Proprietary Chinese Medicines in Wuhan to introduce the relevant procurement rules of the National Alliance of Proprietary Chinese Medicines and solicit opinions and suggestions from enterprises. According to industry analysts, the national centralized procurement of proprietary Chinese medicines may stir up the 3000 billion yuan market for proprietary Chinese medicines.

Jiang Changsong, assistant dean of the National Institute of Medical Security of Capital Medical University, once wrote that the centralized drug procurement system has developed to a volume-based procurement model based on the general idea of "national organization, alliance procurement, and platform operation" and the basic principles of "volume-based procurement, volume-price linkage, integration of solicitation and procurement, guaranteed use, quality assurance, supply guarantee, and payment collection", which will become the most mainstream drug procurement model in China before 2025.

Obviously, under the background of centralized procurement policy, the price reduction of drugs and devices has become the general trend, and patients will eventually benefit after the inflated price is squeezed out. (End)